Ennis & Ennis, P.A. | Personal Injury Attorney

1.800.856.6405

FDA Moves to Restrict Access to Three GSK Diabetes Drugs

- Diabetes Heath

06/13/2011 - The U.S. Food and Drug Administration has said that starting on November 18, 2011, it will restrict retail pharmacy sales of three diabetes drugs manufactured by GlaxoSmithKline: the stand-alone Avandia (rosiglitazone) and the combination drugs Avandamet (rosiglitazone and metformin) and Avandaryl (rosiglitazone and glimepiride).

The market restrictions are motivated by the agency's concerns that the drugs increase the risk of heart attacks. To continue taking the drugs, diabetes patients and their prescribers must be enrolled in the Avandia-rosiglitazone Medicines Access Program, a mail-order program run by FDA-certified pharmacies. To enroll, patients will have to show that they cannot successfully control their blood sugar levels with other drugs.

The FDA restriction is the latest in a series of setbacks for what was once the world's best-selling diabetes drug, peaking at $3.2 billion in worldwide sales in 2006. But concerns about subsequent studies, which raised questions about Avandia's effects on bone density and an increased risk of heart attacks, cut deeply into sales. In 2010, sales were $680 million-down almost 80 percent in four years from their high.

The current number of U.S. Avandia users is hard to determine. The FDA's latest figures, from October 2010, showed 119,000 patients filling prescriptions for it, down substantially from 235,500 patients in January 2010.

Glaxo, which is informing U.S. pharmacies now about the November deadline, has advised pharmacists and healthcare providers to caution patients currently taking Avandia not to stop taking it without consulting a medical professional.

Avandia Side Effects Lawsuit News Archive::

If you or a loved one have experienced an Avandia heart attack, Avandia stroke, Avandia congestive heart failure, Avandia cardiovascular disease or if you have lost a loved one to an Avandia death you may be entitled to compensation. Contact the Avandia attorneys of Ennis & Ennis today for a free confidential case evaluation. Our on staff nurse and lawyers are standing by to answer any questions you may have regarding Avandia, Avandamet or Rosiglitazone side effects, a possible Avandia class action lawsuit, or any other type of Avandia litigation. Fill out the free Avandia case evaluation form on this page or call us toll-free at: 1.800.856.6405.

Under no circumstances should you discontinue taking any medication, including Avandia without first consulting with your doctor

Offices:
Washington DC Office 1101 Pennsylvania Ave. Suite 600 Washington, DC 20004 Telephone: 202.756.2972	Miami Office 1111 Brickell Avenue 11th Floor Miami, FL 33131 Telephone: 305.913.7199	Fort Lauderdale Office 110 E. Broward Blvd. Suite 1700 Fort Lauderdale, FL 33301 Telephone: 954.315.3934 Facsimile: 954.315.3914

Required fields in Red

Name:

Email:

Telephone: (123-123-1234)

Mailing Address:

City:

State:

Zip Code:

On whose behalf are you inquiring?

Is the person deceased?

Yes No

If the person is deceased please list the cause of death as listed on the death certificate:

Please list the date you began and ended using Avandia:

Please list the dosage that was used as well as how many times daily it was taken:

Please list any side effects of Avandia that have been experienced:

When did you seek medical attention for the side effects you listed above?

Please list any additional information you feel may be relevant to your potential Avandia side effects case:

How did you hear about us?

HOME	ABOUT	DRUGS	DEVICES	PRODUCTS	BLOG	LINKS	SITEMAP	CONTACT US
1.800.856.6405